Dirk de Ruysscher (D.K.M.)

Vickers, A. J., McSweeney, D. M., Choudhury, A., Weaver, J., West, C., Kerns, S., Azria, D., Farcy-Jaquet, M. P., Chang-Claude, J., Dunning, A., Lambrecht, M., Avuzzi, B., De Ruysscher, D., Seibold, P., Sperk, E., Talbot, C., Vega, A., Veldeman, L., Bultijnck, R., ... McWilliam, A. (2026). Associations between body composition and radiotherapy-related side-effects and health-related quality of life in patients with prostate or lung cancer: sub-analysis of the REQUITE trial. Radiotherapy and Oncology, 222, Article 111673. https://doi.org/10.1016/j.radonc.2026.111673

van Rossum, P. S. N., Damen, P. J. J., Cortiula, F., Hobbs, B. P., De Marchi, L., Mohan, R., Peters, M., Schneiders, F. L., De Ruysscher, D., Wijsman, R., Verhoeff, J. J. C., Xu, T., Liao, Z., & Lin, S. H. (2026). Pretreatment Risk Model for Radiation-Induced Lymphopenia Is Associated With Adjuvant Durvalumab Efficacy in Patients With Unresectable Stage III NSCLC. International Journal of Radiation Oncology Biology Physics, 125(5), 1434-1444. https://doi.org/10.1016/j.ijrobp.2026.02.238

Sugden, B. M., Witlox, W. J. A., Cortiula, F., Hendriks, L. E. L., van Loon, J., Jacobs, M., Hattu, D., Joore, M. A., Ramaekers, B. L. T., & De Ruysscher, D. K. M. (2026). Assessing the impact of proton versus photon therapy on health-related quality of life in lung cancer. Clinical and Translational Radiation Oncology, 59, Article 101160. https://doi.org/10.1016/j.ctro.2026.101160

Willmann, J., Dee, E. C., Hendriks, L. E. L., Dimitriou, N. M., Jongbloed, M., Schoenfeld, A. J., Drilon, A., Ganesh, K., Zhang, Y. H., Feldman, J., Werner, R., Opitz, I., Carrot-Zhang, J., Schultz, N., Veeraraghavan, H., Jones, D. R., Awad, M., Rudin, C. M., Popat, S., ... Iyengar, P. (2026). Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic Therapies. Journal of Clinical Oncology, 44(16), 1540-1552. https://doi.org/10.1200/JCO-25-01958

Widder, J., Bol, G. M., Simek, I.-M., Ehret, F., Abdel-Aty, H., Basic, S., Chuter, D., Daly, J., Fairbrother, P., Zeqa, D., Nana, F. A., Achard, V., Corradini, S., Correia, D., De Ruysscher, D., Dingemans, A.-M. C., Faivre-Finn, C., Gillessen, S., Guren, M. G., ... Guckenberger, M. (2026). Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC-ESTRO OligoCare consortium. The Lancet Oncology, 27(5), e238-e247. https://doi.org/10.1016/S1470-2045(26)00075-6

Ta, B. D. P., Canters, R. A. M., van der Klugt, K., Vilches-Freixas, G., Kneepkens, E., Vereijken, F., Cobben, M., van den Bosch, M., Lubken, I., Stultiens, C., Velders, M., Verstappen, T., Tholen, G., Niezink, A. G. H., De Ruysscher, D. K. M., & Berbee, M. (2026). Improved organs-of-interest dose reduction potential with intensity modulated proton therapy and breath-hold in mediastinal lymphoma. Physics & Imaging in Radiation Oncology, 39, Article 100996. https://doi.org/10.1016/j.phro.2026.100996

Dingemans, A. M. C., Opitz, I., Brunelli, A., Remon, J., Hendriks, L. E. L., Edwards, J., Faivre-Finn, C., Reguart, N., Smit, E. F., Levy, A., Sanchez-Lorente, D., Trujillo, J. C., Filippi, A. R., Stathopoulos, K., Blum, T. G., Guckenberger, M., Popat, S., De Angelis, R., Hofman, P., ... Berghmans, T. (2026). Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration. The Lancet Respiratory medicine, 14(5), 453-462. https://doi.org/10.1016/S2213-2600(26)00051-2

Saini, K. S., Koopman, M., Martins-Branco, D., Bossi, P., Braendegaard Winther, S., Brahmi, M., Braña, I., Calvo, E., Castelo-Branco, L., Colombo, I., de Azambuja, E., De Ruysscher, D., Dienstmann, R., Dingemans, A. M., Ekholm, M., Gallois, C., Golfinopoulos, V., Grande, E., Halabi, S., ... Et al. (2026). ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours. Annals of Oncology, 37(5), 608-623. https://doi.org/10.1016/j.annonc.2026.02.008

Lee, G., Haugg, F., Bontempi, D., He, J., Zalay, O., Bitterman, D. S., Catalano, P., Prudente, V., Pai, S., Guthier, C., Kann, B. H., De Ruysscher, D., Aerts, H. J. W. L., & Mak, R. H. (2026). FaceAge as a biomarker for prognosis and treatment stratification in a large-scale oncology cohort. Journal of the National Cancer Institute, 118(5), 811-821. https://doi.org/10.1093/jnci/djaf323

Heumann, P., Aguado-Barrera, M. E., Jandu, H. K., Azria, D., Briers, E., Bultijnck, R., Chang-Claude, J., Choudhury, A., Dunning, A. M., Fachal, L., Fuentes-Rios, O., Gomez-Caamano, A., Gutierrez-Enriquez, S., Kaaks, R., Kerns, S. L., Lambrecht, M., Romero, J. C. R., Rosenstein, B. S., De Ruysscher, D., ... REQUITE consortium (2026). Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients. Nature Communications, 17(1), Article 3703. https://doi.org/10.1038/s41467-026-72041-3